Childhood cancer survivors treated with radiotherapy had increased carotid and femoral intima-media thickness and higher t-PA and PAI-I levels compared with sibling controls.
Observational (n=407)
Does potentially cardiovascular toxic anticancer treatment increase vascular damage in long-term childhood cancer survivors compared to sibling controls?
Long-term childhood cancer survivors treated with radiotherapy show signs of persistent endothelial damage and increased intima-media thickness, highlighting the need for cardiovascular risk monitoring in this population.
PURPOSE: To evaluate the presence of vascular damage in long-term childhood cancer survivors (CCS) and sibling controls, and to evaluate the association between vascular damage parameters and cancer treatment and influence of cardiovascular risk factors. PATIENTS AND METHODS: Vascular assessment was performed in 277 adult CCSs (median age at diagnosis, 9 years; range, 0 to 20 years; median current age, 28 years; range, 18 to 48 years) treated with potentially cardiovascular toxic anticancer treatment (ie, anthracyclines, platinum, and/or radiotherapy RT). Measurements included carotid- and femoral-wall intima-media thickness (IMT), flow-mediated vasodilatation of the brachial artery by ultrasound, assessment of endothelial and inflammatory marker proteins (including tissue-type plasminogen activator t-PA, plasminogen activator inhibitor type 1 PAI-I), and cardiovascular risk factors. CCS assessments were compared with those of 130 sibling controls (median age, 26 years; range, 18 to 51 years). RESULTS: At a median of 18 years (range, 5 to 31 years) after treatment, carotid and femoral IMTs in CCSs were not different from those of controls. However, CCSs who received RT as part of their treatment regimen had increased carotid and femoral IMTs and higher t-PA and PAI-I levels, indicating vascular damage and persistent endothelial activation. Patients treated with RT to the neck or chest also had greater femoral IMT. Greater IMT was associated with presence of cardiovascular risk factors (eg, hypertension and overweight). CONCLUSION: After potentially cardiovascular toxic anticancer treatment, CCSs who received RT showed signs of endothelial damage and an unfavorable cardiovascular risk profile compared with controls. CCSs treated with localized RT had increased IMT outside the primary irradiation field. These abnormalities are probably involved in the pathogenesis of cardiovascular morbidity in CCSs.
Brouwer et al. (Tue,) conducted a observational in Childhood cancer survivors (n=407). Potentially cardiovascular toxic anticancer treatment vs. Sibling controls was evaluated on Carotid- and femoral-wall intima-media thickness (IMT) and endothelial/inflammatory markers. Childhood cancer survivors treated with radiotherapy had increased carotid and femoral intima-media thickness and higher t-PA and PAI-I levels compared with sibling controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: